ICER will develop a report on chimeric antigen receptor t-cell (CAR-T) therapies for treatment of B-cell malignancies. ICER’s report is expected to consider the comparative clinical effectiveness and value of tisagenlecleucel (KymriahTM [CTL-019], Novartis) and axicabtagene ciloleucel (KTE-019, Kite Pharma). Tisagenlecleucel was approved by the FDA is August of 2017; an approval decision for axicabtagene ciloleucel is expected in December of 2017, respectively. If approved, tisagenlecleucel-t is expected to be used in the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia in pediatric and young adult patients. Novartis is also expected to file later this year for a second indication for diffuse large B-cell lymphoma in adults. Axicabtagene ciloleucel is under review for the treatment of relapsed or refractory aggressive non-Hodgkin’s lymphoma in adult patients who are not eligible for autologous stem cell transplant.
Date of Review: March 2018
The California Technology Assessment Forum will convene to discuss evidence on CAR-T therapies.
Public meeting of CTAF.